A scan-guided plan let some women with HER2+ breast cancer skip chemotherapy
Five-year results of the PHERGain trial, published Oct. 29, 2026, in Nature Medicine, show that 89.5% of women on a PET-guided plan were free of invasive disease, and 92.4% of those who…